Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms

To investigate the association between esomeprazole pharmacokinetics and CYP2C19 gene polymorphisms in a cohort of 95 healthy Chinese participants. A cohort of 95 participants was assembled and stratified into 2 distinct groups, receiving either 20 or 40 mg of esomeprazole through oral administratio...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology in drug development 2024-02, Vol.13 (2), p.134-139
Main Authors: Fang, Yuan, He, Xia, Peng, Ai, Yang, Yi qi, Xiang, Jin
Format: Article
Language:English
Subjects:
Aryl Hydrocarbon Hydroxylases - genetics
Aryl Hydrocarbon Hydroxylases - metabolism
Cytochrome P-450 CYP2C19 - genetics
Esomeprazole
Genotype
HPLC
Humans
Pharmacokinetics
Polymorphism, Genetic
safety
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the association between esomeprazole pharmacokinetics and CYP2C19 gene polymorphisms in a cohort of 95 healthy Chinese participants. A cohort of 95 participants was assembled and stratified into 2 distinct groups, receiving either 20 or 40 mg of esomeprazole through oral administration. The subjects encompassed 17 poor metabolizers, 47 intermediate metabolizers, and 31 rapid metabolizers, and their genotypes were ascertained using the polymerase chain reaction–restriction fragment length polymorphism technique. Esomeprazole plasma concentrations were quantified employing a high‐performance liquid chromatography–ultraviolet method. Pharmacokinetic parameters were computed via Phoenix WinNonlin 6.1 software, while SPSS 26.0 facilitated statistical analysis to contrast the pharmacokinetics and the CYP2C19 genotypes. In the aftermath of administering 20 or 40 mg esomeprazole, marked differences were discerned between terminal elimination half‐life, maximum concentration/dose, and area under the plasma concentration–time curve from time zero to infinity/dose of esomeprazole (P 
ISSN:2160-763X
2160-7648
DOI:10.1002/cpdd.1334